Diagonal Bio AB (publ) (DIABIO.ST)
STO
Healthcare
Biotechnology
$0.01
▲ +0.00%
Market Cap
$20.2M
Sector
Healthcare
Industry
Biotechnology
Beta
-1.85
52-Wk Range
0.012-0.016
CEO
Karin E. Wehlin
Country
SE
Currency
SEK
Diagonal Bio AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SE. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $20.2M. Its beta of -1.85 implies it has historically moved less than the broad market.
Company profile
Exchange
Stockholm Stock Exchange
Employees
4
IPO date
2021-07-16
Headquarters
Lund, SE
About Diagonal Bio AB (publ)
Diagonal Bio AB is a Swedish biotechnology firm dedicated to advancing the Panviral platform. This innovative technology is engineered to pinpoint and diagnose minute genetic fragments belonging to a range of pathogens, such as viruses, bacteria, and fungi. Established in 2020, the company's main operations are based in Lund, Sweden.
Comparable companies
Diagonal Bio AB (publ) is most often compared with the following Healthcare names:
More research on DIABIO.ST
Open full interactive analysis & DCF →